ADCT-212 / ADC Therapeutics - LARVOL DELTA

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PRNewswire) - "ADC Therapeutics SA...announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ('PIPE') financing....Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses....ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts primarily in support of ZYNLONTA clinical development as well as ZYNLONTA commercialization activities, working capital and general corporate purposes....Beyond ZYNLONTA, the Company will advance its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA) and will discontinue early development efforts for the remaining preclinical programs in solid tumors."

Discontinued • Financing • Diffuse Large B Cell Lymphoma • Solid Tumor

Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers (AACR 2023) - "ADCT-212 was tolerated as a single 20 mg/kg dose in male rats, with exposure data being indicative of a linear PK profile with a half-life of approximately 12 days. In conclusion, ADCT-212 demonstrated potent and specific in vitro and in vivo anti-tumor activity while it was stable and well tolerated in the rat, warranting further development of ADCT-212 into the clinic."

Preclinical • Colon Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones....ADCT-212 (targeting PSMA): Initiate Phase 1 study in 1H 2024. ADCT-602 (targeting CD22): Complete Phase 1 dose expansion study in 1H 2024. ADCT-701 (targeting DLK-1): Initiate Phase 1 study in 2H 2023."

New P1 trial • Trial status • Oncology

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (Businesswire) - "ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022)...ADCT-212 (targeting PSMA)- Progress toward IND filing and initiation of Phase 1 trial in 2023; ADCT-701 (targeting DLK-1)- Progress toward IND filing and initiation of Phase 1 trial in 2023."

IND • Sales • Hematological Malignancies • Oncology • Solid Tumor

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones: ZYNLONTA...Initiate the LOTIS-9 trial of ZYNLONTA + rituximab in 1L unfit/frail DLBCL patients in 2H 2022; Initiate the LOTIS-7 trial of ZYNLONTA in multiple combinations in NHL in 1H 2022; Cami: Report topline results for the Phase 2 trial in HL in 1H 2022; Meet with FDA for pre-BLA meeting in 2H 2022; ADCT-601 (targeting AXL): Initiate the Phase 1b combination study in multiple solid tumors in 1H 2022; ADCT-701 (targeting DLK1): Continue to work with the NCI for completion of preclinical studies to support an IND filing; ADCT-212 (targeting PSMA): Continue completion of preclinical studies to support an IND filing."

IND • New P1 trial • New trial • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor